SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that its abstract for a poster on “18-Plex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput System” has been accepted for presentation at the Association for Molecular Pathology meeting, November 5-7 in Austin, TX.
The poster will cover the development progress of Applied BioCode’s new high throughput, multiplex automated MDx system. The new BioCode platform utilizes Applied BioCode’s proprietary Barcoded Magnetic Beads (BMB) and fully automates the process of amplification, target capture and detection for molecular diagnostic assays.
The poster will also provide the latest analytical and performance data for the 18-plex Gastrointestinal Pathogen Panel that is currently in development. The BioCode 18-plex GI Pathogen Panel includes targets for the bacteria (Campylobacter, Clostridium difficile toxin A&B, Salmonella, Shigella, E. coli O157, Enterotoxigenic E. coli, Enteropathogenic E. coli, Shiga toxin producing E. coli, Enteroaggregative E. coli, Vibrio spp., Vibro parahaemolyticus, Vibro Vulnificus, Vibro Cholerae, Yersinia Enterocolitica), viruses (norovirus group I/II, adenovirus 40/41, rotavirus A), and parasites (Giardia, Cryptosporidium, Entamoeba histolytica).
Preliminary data generated for the Gastrointestinal Pathogen Panel with the automated system will be presented by Applied BioCode’s scientific personnel.
About Applied BioCode, Inc.
Applied BioCode is a privately held biotechnology company that develops, manufactures, and markets Barcoded Magnetic Beads (BMB) and detection systems to facilitate development of highly multiplexed nucleic acids or protein detection assays. BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy. It is well suited for clinical diagnostic applications such as detection of infectious agents, drug resistance markers, cancer markers and mutation analysis, as well as for life science research and agricultural testing markets.
Currently, we are in the process of developing multiplex infectious disease detection assays and a user friendly, high throughput system based on proprietary BMB technology for Molecular Diagnostics testing. With dedicated mission on improved patient care, our platform and multiplex assays will provide cost effective, rapid and wide-ranging detection of pathogens that can cause serious and life threatening infections within hospitals and their surrounding communities.